English, Article edition: Which Antifungal Agent for Onychomycosis?: A Pharmacoeconomic Analysis Vijay N. Joish; Edward P. Armstrong

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94389
Physical Description
  • article
Language
  • English

Edition details

Title
  • Which Antifungal Agent for Onychomycosis?: A Pharmacoeconomic Analysis
Author
  • Vijay N. Joish
  • Edward P. Armstrong
Physical Description
  • article
Notes
  • The incidence of fungal nail infections is increasing and this is possibly because of several factors: better methods of detection, a growing population of immunocompromised patients who have a greater susceptibility to such infections, the increased use of immunosuppressive drugs, the increasing number of elderly people, worldwide travel, and the use of communal bathing facilities. Onychomycosis is a fungal infection of the fingernails and toenails that accounts for about 30% of all superficial fungal infections. It is characterised by nail discoloration, thickening and ultimately destruction of the nail plate. Management of this disease has improved significantly and treatment patterns have dramatically changed in recent years as a result of advances in new treatment options (e.g. oral antifungal agents) and changes in treatment regimens (e.g. pulse therapy). Also, newer drugs for onychomycosis have improved tolerability profiles compared with older agents. The overall costs of treating onychomycosis are substantial, and it has been estimated that direct cost for US Medicare patients with the disease is $US43 million per year (year of costing not available). Pharmacoeconomic studies help in the decision-making process when selecting the most cost-effective antifungal agents to treat onychomycosis. To date there have been a number of national and international economic studies aimed at effectively assessing the efficacy and costs of the treatment options available to cure onychomycosis. The objectives of this paper are to 1. review the published findings regarding the epidemiology of onychomycosis; 2. summarise the original pharmacoeconomic studies that describe the economic impact of the disease; and 3. address the impact of the disease on patients' health-related quality of life.
  • Antifungals, Cost analysis, Fluconazole, Griseofulvin, Itraconazole, Ketoconazole, Onychomycosis, Pharmacoeconomics, Terbinafine
  • RePEc:wkh:phecon:v:19:y:2001:i:10:p:983-1002
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment